NV-TELUS-CORPORATION
4.2.2020 10:02:08 CET | Business Wire | Press release
TELUS Corporation (T-TSX; NYSE-TU) and its global arm, TELUS International - a customer experience innovator that designs, builds and delivers next-generation digital solutions for some of the world’s most established brands, today confirmed the close of their previously announced acquisition of Competence Call Center (CCC). TELUS International now holds a 100% interest in CCC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005273/en/
The merged company has an expanded portfolio of customer experience, digital transformation, content moderation, IT lifecycle, advisory and digital consulting, risk management, and back-office support that will enable new go-to-market opportunities and drive growth.
“We are committed to creating a friendlier future for citizens globally; one in which technology supports the security and integrity of the data and information we process every day,” said Darren Entwistle, President and CEO of TELUS. “Through this important acquisition, our TELUS International team will benefit from the thought leadership, skill and dynamic insights of more than 8,500 CCC employees across 11 European countries, supporting our global customers with innovative digital solutions. We are thrilled to welcome these new team members to our TELUS International family. Importantly, this represents our largest ever international transaction, as we augment our TELUS International employee base to almost 50,000 team members, delivering service and support in over 50 languages from more than 50 delivery centres in 20 countries across North and Central America, Europe and Asia.”
“We’re so pleased to see the culmination of our team’s remarkable efforts, passion and diligence with the merger of TELUS International and CCC - two like-minded organizations similarly focused on putting customers first, caring for team members, and investing in the communities where we operate,” said Jeff Puritt, President and CEO, TELUS International. “In addition to the many benefits stemming from the significant influx of top industry talent, CCC’s core business and complementary products, services, locations and languages will enable us to access new high-growth markets and position us as a valuable strategic partner that can deliver innovative end-to-end solutions for clients.”
“CCC is TELUS International’s third sizeable acquisition in less than three years, further fueling our momentum to achieve impressive growth targets and establish an enhanced scope of global operations, while simultaneously gaining the requisite depth and breadth of expertise in next-gen technology and content moderation to differentiate ourselves and compete aggressively in the marketplace,” continued Puritt. “These successful mergers, in conjunction with ongoing healthy organic growth that includes new sites opened in Guatemala City, Chengdu and Manila in 2019, have provided the necessary scale and breadth to realize a meaningfully expanded enterprise value and contemplate a public listing in the next 12 to 24 months, positioning TELUS International for continued growth in the years to come.”
TELUS International will continue to focus on partnering with clients in the fast-growing tech, travel and hospitality, financial services and fintech, telecommunications, games and healthcare industries, and CCC has an established presence in the content moderation space, counting large, well known global brands and social media companies as its customers.
"Today is an extraordinary and remarkable day in the successful 22-year journey of our company," said Christian Legat, CEO, CCC. "With the official close of our partnership with TELUS International, we are excited to begin realizing the numerous benefits of bringing together our highly-engaged teams to pool our knowledge and skills, as well as our companies’ resources and geographic footprints to deliver more fulsome, first-class customer experiences from more regions around the world.”
The acquisition is expected to add significant scale to TELUS International, an important and differentiated growth driver for TELUS, and will support TELUS’ consolidated financial and operating results including revenue, EBITDA and free cash flow growth as previously disclosed. The acquisition of CCC will be immediately revenue and EBITDA accretive to TELUS and TELUS International, as well as EBITDA margin accretive to TELUS International. Additionally, given the low capital intensity of the combined businesses, the transaction is also expected to support immediate free cash flow expansion.
Both companies have earned numerous industry accolades over the years. Most recently, TELUS International received an Achievers 50 Most Engaged Workplaces® Award for the third consecutive year in 2019 and Gold in the Employer of the Year category for Business Services at the 2019 Stevie® Awards for Great Employers, and CCC was honoured with the 2019 CCV Quality Award for customer satisfaction.
Barclays and Rothschild & Co served as joint financial advisors and Shearman & Sterling LLP served as legal counsel to TELUS International for this transaction.
About TELUS
TELUS (TSX: T, NYSE: TU) is a dynamic, world-leading communications and information technology company with CAD$15 billion in annual revenue and 15 million customer connections spanning wireless, data, voice, entertainment, security and health solutions. We leverage our global-leading technology to enable remarkable human outcomes. Our longstanding commitment to putting our customers first fuels every aspect of our business, making us a distinct leader in customer service excellence and loyalty. Driven by our passionate purpose to lead the world in social capitalism, our deeply meaningful and enduring philosophy to give where we live has inspired our team members and retirees to contribute more than CAD$700 million and 1.4 million days of service since 2000. This unprecedented generosity and unparalleled volunteerism have made TELUS the most giving company in the world. For more information about TELUS, please visit telus.com .
About TELUS International
TELUS International focuses on the value of human connection to design, build and deliver high-tech, high-touch customer experiences powered by next-gen digital solutions. With almost 50,000 team members as well as delivery centers across North and Central America, Europe and Asia, TELUS International empowers customer experience innovation through digital enablement, spirited teamwork, agile thinking, and a caring culture that puts customers first. The company's solutions cover customer experience, digital transformation, content moderation, IT lifecycle, advisory and digital consulting, risk management, and back-office support. Fueling all stages of company growth, TELUS International partners with some of the world’s most disruptive brands from fast-growing tech, financial services and fintech, games, travel and hospitality, and healthcare industries. The company serves clients in over 50 languages. TELUS holds a ~63% interest in TELUS International with Baring Private Equity Asia and Competence Call Center management holding the remaining ~33% and ~3%, respectively. Learn more at: telusinternational.com
Forward-looking statements:
This news release contains statements about expected future events, including, but not limited to, statements relating to the expected benefits of the transaction, enterprise value and plans for its integration and potential plans and timing of an initial public offering (IPO) by TELUS International. By their nature, forward-looking statements require TELUS to make assumptions and predictions and are subject to inherent risks and uncertainties. There can be no assurance that the expected benefits of the transaction will be realized or that an IPO by TELUS International will be completed within the targeted time frame or at all. There is a significant risk that the forward-looking statements will not prove to be accurate. The forward-looking statements contained in this news release describe our expectations at the date of this news release and, accordingly, are subject to change after such date. Readers are cautioned not to place undue reliance on forward-looking statements as a number of factors could cause actual future events to differ materially from those expressed in the forward-looking statements. Accordingly, this news release is subject to the disclaimer and qualified by the assumptions, qualifications and risk factors referred to in TELUS' 2019 third quarter Management’s discussion and analysis and 2018 annual report, and in other TELUS public disclosure documents and filings with securities commissions in Canada (on SEDAR at sedar.com ) and in the United States (on EDGAR at sec.gov ). Except as required by law, TELUS disclaims any intention or obligation to update or revise forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005273/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
